UV-A pp 221-240 | Cite as

Uses of UV-A Involving Exposure of Humans

  • John A. Parrish
  • R. Rox Anderson
  • Frederick Urbach
  • Donald Pitts


The uses of UV-A in medicine and industry are expanding. Such applications generally employ UV-A-induced fluorescence as a diagnostic tool, or useful UV-A photochemical or photobiologic reactions. In industry, UV-A-induced fluorescence is used to detect flaws in metal castings. Industrial use of UV-A photochemical reactions includes the curing of coating materials, inks, and adhesives and the reprogramming of programmable integrated circuits in the electronics industry.


Sister Chromatid Exchange Mycosis Fungoides Tinea Capitis Porphyria Cutanea Tarda PUVA Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gilchrest, B. A., Rowe, J. W., Brown, R. S., Steinman, T., and Arndt, K. Relief in uremic pruritus with ultraviolet phototherapy. N. Engl. J. Med. 297: 136–138, 1977.Google Scholar
  2. 2.
    Sisson, T. R. Visible light therapy of neonatal hyperbilirubinemia. In Photochemical and Photobiological Reviews, Vol. 1 (K. C. Smith, Ed.). Plenum Press, New York, 1976, pp. 241–268.Google Scholar
  3. 3.
    Elder, R. L. Comment: Hazard of ultraviolet radiation from fluorescent lamps to infant during photherapy. J. Pediatr. 84: 145, 1974.Google Scholar
  4. 4.
    Behrman, R. E., Brown, A. K., Currie, M. R., Hastings, J. W., Odell, G. B., Schaffer, R., Setlow, R. B., Vogl, T. P., Wurtman, R. J., Anderson, R. J., Koskowski, H. J., and Simopoulos, A. P. Preliminary report of the committee on phototherapy in the newborn infant. J. Pediatr. 84: 135–143, 1974.Google Scholar
  5. 5.
    Parrish, J. A., Fitzpatrick, T. B., Tanenbaum, L., and Pathak, M. A. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N. Engl. J. Med. 297: 1207–1212, 1974.Google Scholar
  6. 6.
    Wolff, K., Fitzpatrick, T. B., Parrish, J. A., Gschnait, F., Gilchrest, B., Honigsmann, H., Pathak, M. A., and Tanenbaum, L. Photochemotherapy for psoriasis with orally administered methoxsalen. Arch. Dermatol. 67: 669–671, 1976.Google Scholar
  7. 7.
    Parrish, J. A. Treatment of psoriasis with longwave ultraviolet light. Arch. Dermatol., 775: 1525–1528. 1977.Google Scholar
  8. 8.
    Goeckerman, W. H. The treatment of psoriasis. Northwest Med. 24: 229–231, 1925.Google Scholar
  9. 9.
    Goeckerman, W. H. Treatment of psoriasis: Continued observations on the use of crude coal tar and ultraviolet light. Arch. Dermatol. Syphilol. 24: 446–450, 1931.Google Scholar
  10. 10.
    Young, E. Ultraviolet therapy of psoriasis: A critical study. Br. J. Dermatol. 57: 379–382, 1972.Google Scholar
  11. 11.
    Ellis, D. D., Woodbridge, W. E., and Weiss, R. S. The treatment of psoriasis with liquor carbonis detergents, a modification of the Goeckerman treatment. J. Invest. Dermatol. 70: 445–458, 1948.Google Scholar
  12. 12.
    Bowers, R. E., Dalton, D., Fursdon, D., and Knoweldon, J. The treatment of psoriasis with UVR, dithranol paste and tar baths. Br. J. Dermatol. 75: 273–281, 1966.Google Scholar
  13. 13.
    Marsico, A. R., and Eaglstein, W. H. Role of longwave ultraviolet light in Goeckerman treatment. Arch. Dermatol. 705: 48–49, 1973.Google Scholar
  14. 14.
    Crow, K. D., Alexander, E., Buck, W. H. L., Johnson, B. E., Magnus, I. A., and Porter, A. D. Photosensitivity due to pitch. Br. J. Dermatol. 73: 220–232, 1961.Google Scholar
  15. 15.
    Everett, M. A., and Miller, J. V. Coal tar and ultraviolet light. II. Cumulative effects. Arch. Dermatol. 54: 937–940, 1961.Google Scholar
  16. 16.
    Tanenbaum, L., Parrish, J. A., Pathak, M. A., Anderson, R. R., and Fitzpatrick, T. B. Tar photoxicity and phototherapy for psoriasis. Arch. Dermatol. 777: 467–470, 1975.Google Scholar
  17. 17.
    Parrish, J. A., Morison, W. L., Gonzalez, E., Krop, T., White, H. A. D., and Rosario, R. Therapy of psoriasis by tar photosensitization. J. Invest. Dermatol., 70: 111–112, 1978.Google Scholar
  18. 18.
    Dougherty, T. J., Grindey, G. B., Fiel, R., Weishaupt, K. R., and Boyle, D. G. Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light. J. Nat. Cancer Inst. 55: 115–119, 1975.Google Scholar
  19. 19.
    Dougherty, T. J., Kaufman, J. H., Goldfarb, A., Johnson, R., Boyle, D. G., and Weishaupt, K. R. Photoradiation therapy of malignant tumors: An initial clinical trial. Abstract presented at 25th Anniversary Meeting of the Radiation Research Society, May 8–12, 1977, San Juan, Puerto Rico, p. 49.Google Scholar
  20. 20.
    Tomson, S. H., Emmett, E. A., and Fox, S. H. Photodestruction of mouse epithelial tumors after oral acridine orange and argon laser. Cancer Res. 54: 3124–3127, 1974.Google Scholar
  21. 21.
    Lerner, A. B., Denton, C. R., and Fitzpatrick, T. B. Clinical and experimental studies with 8-methoxypsoralen in vitiligo. J. Invest. Dermatol. 20: 299–314, 1953.Google Scholar
  22. 22.
    Lerner, A. B. Potentiation of suntanning through ingestion of 8-methoxypsoralen. J. Invest. Dermatol. 25: 1, 1955.Google Scholar
  23. 23.
    Fitzpatrick, T. B., Hopkins, C. E., Blickenstaff, D. D., and Swift, S. Augmented pigmentation and other responses of normal human skin to solar radiation following oral administration of 8-methoxypsoralen. J. Invest. Dermatol. 25: 187–190, 1955.Google Scholar
  24. 24.
    Daniels, F., Hopkins, C. E., Imbrie, J. D., Bergeron, L., Miller, O., Crowe, F., and Fitzpatrick, T. B. Field trials of the suntan promoting effect of methoxsalen. J. Invest. Dermatol. 32: 321–329, 1959.Google Scholar
  25. 25.
    Imbrie, J. D., Daniels, F., Jr., Bergeron, L., Hopkins, C. E., and Fitzpatrick, T. B. Increased erythema threshold six weeks after a single exposure to sunlight plus oral methoxsalen. J. Invest. Dermatol. 52: 331–337, 1959.Google Scholar
  26. 26.
    Kanof, N. B. Clinical experience with the effect of oral-8-methoxypsoralen of the pigmentary responses of the skin to sunlight. J. Invest. Dermatol. 52: 343–344, 1959.Google Scholar
  27. 27.
    Stegmaier, O. The use of methoxsalen in suntanning. J. Invest. Dermatol. 32: 345–349, 1959.Google Scholar
  28. 28.
    Pathak, M. A., Kramer, D. M., and Fitzpatrick, T. B. Photobiology and photochemistry of furocoumarins (psoralens). In Sunlight and Man: Normal and Abnormal Photobiologic Responses (M. A. Pathak, L. C. Harber, M. Seiji, and A. Kukita, Eds.; T. B. Fitzpatrick, Consulting Ed.). University of Tokyo Press, Tokyo, 1974, pp. 335–368.Google Scholar
  29. 29.
    El-Mofty, A. M. A preliminary clinical report on the treatment of leukoderma with,4mm/ majus Linn. J. Roy. Egyptian Med. Assoc. 57: 651, 1948.Google Scholar
  30. 30.
    Fahmy, I. R., and Abu-Shady, H. Ammi majus Linn. Pharmacognostical study and isolation of crystalline constituent, Amoidin. Q. J. Phar. Pharmacol. 20: 281, 1947.Google Scholar
  31. 31.
    Fahmy, I. R., and Abu-Shady, H. The isolation and properties of Ammoidin, Ammidin and Majudin and their effect in the treatment of leukoderma. Q. J. Pharm. Pharmacol. 27: 499–503, 1948.Google Scholar
  32. 32.
    Fahmy, I. R., Abu-Shady, H., Schonberg, A., and Sina, A. A crystalline principle from Ammi majus L. Nature 760: 468–469, 1947.Google Scholar
  33. 33.
    Schonberg, A., and Sina, A. Xanthotoxin from the fruits of Ammi majus L. Nature 767: 481–482, 1948.Google Scholar
  34. 34.
    Fitzpatrick, T. B., Parrish, J. A., and Pathak, M. A. Phototherapy of vitiligo (idiopathic leukoderma). In Sunlight and Man: Normal and Abnormal Photobiologic Responses (M. A. Pathak, L. C. Harber, M. Seiji, and A. Kukita, Eds.; T. B. Fitzpatrick, Consulting Ed.). University of Tokyo Press, Tokyo, 1974, pp. 131–141.Google Scholar
  35. 35.
    Kanof, N. B. Melanin formation in vitiliginous skin under the influence of external applications of 8-methoxypsoralen. J. Invest. Dermatol. 24: 5–10, 1955.Google Scholar
  36. 36.
    Kelly, E. W., and Pinkus, H. Local application of 8-methoxypsoralen in vitiligo. J. Invest. Dermatol. 25: 453–456, 1955.Google Scholar
  37. 37.
    Elliot, J. A., Jr. Methoxsalen in the treatment of vitiligo: An appraisal of the permanency of the repigmentation. Arch. Dermatol. 79: 237–243, 1959.Google Scholar
  38. 38.
    Fitzpatrick, T. B., Arndt, K. A., El-Mofty, A. M., and Pathak, M. A. Hydroquinone and psoralens in the therapy of hypermelanosis and vitiligo. Arch. Dermatol. 93: 589–600, 1966.Google Scholar
  39. 39.
    Fulton, J. E., Jr., Leyden, J., and Papa, C. Treatment of vitiligo with topical methoxsalen and blacklight. Arch. Dermatol. 100: 224–229, 1969.Google Scholar
  40. 40.
    Bleehen, S. S. Treatment of vitiligo with oral 4,5′,8-trimethylpsoralen (trisoralen). Br. J. Dermatol. 86: 54–60, 1972.Google Scholar
  41. 41.
    Levin, R. E., and Parrish, J. A. Phototherapy of vitiligo. Lighting Design and Application, 5: 35–43, 1975.Google Scholar
  42. 42.
    Parrish, J. A., Fitzpatrick, T. B., Shea, C., and Pathak, M. A. Photochemotherapy of vitiligo with oral psoralen and a new high-intensity longwave ultraviolet light (UV-A) system. Arch. Dermatol. 112: 1531–1534, 1976.Google Scholar
  43. 43.
    Kligman, A. M., and Goldstein, F. P. Ineffectiveness of trioxsalen as an oral photosensitizer. Arch. Dermatol. 107: 413–414, 1973.Google Scholar
  44. 44.
    Allyn, B. Studies on phototoxicity in man and laboratory animals. Presented at the 21st Annual Meeting of the American Academy of Dermatology, December 1–6, Chicago, 1962.Google Scholar
  45. 45.
    Tronnier, H., and Schule, D. First results of therapy with longwave U V after photosensitization of skin. In Book of Abstracts, Symposia, and Contributed Papers, 6th International Congress of Photobiology. G. O. Schenck, Bochum, Germany, August 1972.Google Scholar
  46. 46.
    Walter, J. F., and Voorhees, J.J. Psoriasis improved by psoralen plus black light. Acta Derm. Venereol. (Stockh.) 55: 469–472, 1973.Google Scholar
  47. 47.
    Mortazawi, S. A. M., and Oberste-Lehn, H. Lichtsensibilisatoren und ihre therapeutischen Fähigkeiten. Z. Haut. Geschl. Krk. 48: 1–9, 1973.Google Scholar
  48. 48.
    Willis, I., and Harris, D. R. Resistant psoriasis: Combined methoxsalen anthralin therapy. Arch. Dermatol. 707: 358–362, 1973.Google Scholar
  49. 49.
    Tronnier, H., and Schule, D. Zur dermatologischen Therapie von Dermatosen mit langwelligen UV nach Photosensibilisierung der Haut mit Methoxsalen: Erste Ergebnisse bei der Psoriasis vulgaris. Z. Haut. Geschl. Krk. 48: 385–393, 1973.Google Scholar
  50. 50.
    Weber, G. Combined 8-methoxypsoralen and black light therapy of psoriasis: Technique and results. Br. J. Dermatol. 90: 317–323, 1974.Google Scholar
  51. 51.
    Fischer, T., and Juhlin, L. Trioxsalen bath and ultraviolet light treatment of psoriasis. Arch. Dermatol. 773: 852, 1977.Google Scholar
  52. 52.
    Fischer, T. Trioxsalen and ultra violet-A in the treatment of psoriasis. In Psoriasis: Proceedings of the Second International Symposium (E. M. Färber and A. J. Cox, Eds.). Yorke Medical Books, New York, 1977, pp. 478–479.Google Scholar
  53. 53.
    Born, W., and Born, A. L. Psoralen bath clearing of widespread psoriasis recalcitrant to oral PUVA therapy. Castellania 5 (10): 191–194, 1977.Google Scholar
  54. 54.
    Swanbeck, G., Thyresson-Hok, M., Bredberg, A., and Lambert, B. Treatment of psoriasis with oral psoralens and longwave ultraviolet light. Acta Derm. Venereol. (Stockh.) 55: 367–376, 1975.Google Scholar
  55. 55.
    Weinstein, G. D., and Frost, P. Abnormal cell proliferation in psoriasis. J. Invest. Dermatol. 50: 254–259, 1968.Google Scholar
  56. 56.
    Epstein, J. H., and Fukuyama, K. A study of 8-methoxypsoralen-induced phototoxic effects on mammalian epidermal macromolecule synthesis in vivo. Photochem. Photobiol. 27: 325–330, 1975.Google Scholar
  57. 57.
    Baden, H. P., Parrington, J. M., Delhanty, J. D. A., and Pathak, M. A. DNA synthesis in normal and xeroderma pigmentosum fibroblasts following treatment with 8-methoxypsoralen and longwave ultraviolet light. Biochim. Biophys. Acta 262: 247–255, 1972.Google Scholar
  58. 58.
    Walter, J. F., Voorhees, J. J., Kelsey, W. H., and Duell, E. A. Psoralen plus black light inhibits epidermal DNA synthesis. Arch. Dermatol. 707: 861–865, 1973.Google Scholar
  59. 59.
    Pathak, M. A., and Kramer, D. M. Photosensitization of skin in vivo by furocoumarins (psoralens). Biochim. Biophys. Acta 795: 197–206, 1969.Google Scholar
  60. 60.
    Cole, R. S. Light-induced cross-linking of DNA in the presence of a furocoumarin (psoralen). Biochim. Biophys. Acta 277: 30–39, 1970.Google Scholar
  61. 61.
    Dall’Acqua, F., Marciani, S., Ciavatta, L., and Rodighiero, G. Formation of interstrand crosslinks in the photoreactions between furocoumarins and DNA. Z. Naturforsch. Teil B 26: 561–569, 1971.Google Scholar
  62. 62.
    Melski, J., Tanenbaum, L., Parrish, J. A., Fitzpatrick, T. B., Bleich, H. L., and 28 Participating Investigators. Oral methoxsalen photochemotherapy for the treatment of psoriasis: A cooperative clinical trial. J. Invest. Dermatol. 65: 328–335, 1977.Google Scholar
  63. 63.
    Durham, G. A., and Morgan, J. K. A 7-year follow-up study of ninety patients with psoriasis. Br. J. Dermatol. 97: 7–11, 1974.Google Scholar
  64. 64.
    Janula, J., and Novotny, F. Zur statistischen Erforschung der Psoriasis. Hautarzt 76: 241–246, 1965.Google Scholar
  65. 65.
    Lever, W. F. Mycosis fungoides. In Histopathology of the Skin (4th ed). Lippincott, Philadelphia, 1967, pp. 752–759.Google Scholar
  66. 66.
    Levi, J. A., and Wiernik, P. H. Management of mycosis fungoides—Current status and future prospects. Medicine (Baltimore) 54: 73–88, 1975.Google Scholar
  67. 67.
    Samman, P. D. Survey of reticuloses and permycotic eruptions: A preliminary report. Br. J. Dermatol. 76: 1–9, 1964.Google Scholar
  68. 68.
    Ackerman, A. B., Breze, T. S., and Capland, L. Spongiotic simulants of mycosis fungoides. Arch. Dermatol. 709: 218–220, 1974.Google Scholar
  69. 69.
    Fisher, E. R., Horvat, B. L., and Wechsler, H. L. Ultrastructural features of mycosis fungoides. Am. J. Clin. Pathol. 58: 99–110, 1972.Google Scholar
  70. 70.
    Flaxman, A. B., Zelazny, G., and Van Scott, E. J. Nonspecificity of characteristic cells in mycosis fungoides. Arch. Dermatol. 704: 141–147, 1971.Google Scholar
  71. 71.
    Lutzner, M. A., Hobbs, J. W., and Horvath, P. Ultrastructure of abnormal cells. Arch. Dermatol. 703: 375–386, 1971.Google Scholar
  72. 72.
    Farber, E. M., Zackheim, H. S., McClintock, R. P., and Cox, A. J., Jr. Treatment of mycosis fungoides with various strengths of fluocinolone acetonide cream. Arch. Dermatol. 97: 165–172, 1968.Google Scholar
  73. 73.
    Van Scott, E. J., and Kalmanson, J. D. Complete remissions of mycosis fungoides lymphoma induced by topical nitrogen mustard. Cancer 32: 18–30, 1973.Google Scholar
  74. 74.
    Haynes, H. A., and Van Scott, E. J. Therapy of mycosis fungoides. Prog. Dermatol. 5: 1–5, 1968.Google Scholar
  75. 75.
    Szur, L. Radiotherapy of the skin reticuloses. Br. J. Dermatol. 76: 10–20, 1964.Google Scholar
  76. 76.
    Fromer, J. L., Johnston, D. O., Salzman, F. A., Trump, J. G., and Wright, K. A. Management of lymphoma cutis with low megavolt electron beam therapy. South. Med. J. 54: 169–776, 1961.Google Scholar
  77. 77.
    Fuks, Z. Y., and Bagshaw, M. A. Total skin electron treatment of mycosis fungoides. Ther. Radiol. 700: 145–150, 1971.Google Scholar
  78. 78.
    Fuks, Z. Y., Bagshaw, M. A., and Farber, E. M. Prognostic signs and the management of the mycosis fungoides. Cancer 52: 1385–1395, 1973.Google Scholar
  79. 79.
    Grollman, J. H., Jr., Bierman, S. M., Ottoman, R. E., Morgan, J. E., and Horns, J. Total- skin electron beam therapy of lymphoma cutis and generalized psoriasis: Clinical experiences and adverse reactions. Radiology 87: 908–915, 1966.Google Scholar
  80. 80.
    deBast, C., Moríame, N., Wanet, J., Ledoux, M., Achten, G., and Kenis, Y. Bleomycin in mycosis fungoides and reticulum cell lymphoma. Arch. Dermatol. 704: 508–512, 1971.Google Scholar
  81. 81.
    Epstein, E. H., Levin, D. L., Croft, J. D., and Lutzner, M. A. Mycosis fungoides: Survival, prognostic features, response to therapy and autopsy findings. Medicine (Baltimore) 57: 61–72, 1972.Google Scholar
  82. 82.
    McDonald, C. J., and Calabresi, P. Azarabine for mycosis fungoides. Arch. Dermatol. 705: 158–167, 1971.Google Scholar
  83. 83.
    Spiegel, S. C., and Coltman, C. A., Jr. Therapy of mycosis fungoides with bleomycin. Cancer 32: 161–110, 1973.Google Scholar
  84. 84.
    Van Scott, E. J., Auerbach, R., and Clendenning, W. E. Treatment of mycosis fungoides with cyclophosphamide. Arch. Dermatol. 55: 107–109, 1962.Google Scholar
  85. 85.
    Wright, J. C., Lyons, M. M., Walker, D. G., Golomb, F. M., Gumport, S. L., and Medrek, T. J. Observations on the use of cancer chemotherapeutic agents in patients with mycosis fungoides. Cancer 17: 1045–1062, 1964.Google Scholar
  86. 86.
    Klein, E., Burgess, G. H., and Helm, F. Neoplasms of the skin. In Cancer Medicine (1st ed.) (J. F. Holland and E. Frei, III, Eds.). Lee & Febiger, Philadelphia, 1973, pp. 1789–1822.Google Scholar
  87. 87.
    Van Scott, E. J., and Haynes, H. A. Cutaneous lymphomas. In Dermatology in General Medicine (T. B. Fitzpatrick, K. A. Arndt, W. H. Clark, A. Z. Eisen, E. J. Van Scott, and J. H. Vaughan, Eds.). McGraw-Hill, New York, 1971, pp. 557–567.Google Scholar
  88. 88.
    Gilchrest, B. A., Parrish, J. A., Tanenbaum, L., Haynes, H. A., and Fitzpatrick, T. B. Oral methoxsalen photochemotherapy of mycosis fungoides. Cancer 38: 683–689, 1976.Google Scholar
  89. 89.
    Morison, W. L., Parrish, J. A., and Fitzpatrick, T. B. Oral psoralen photochemotherapy of atopic eczema. J. Invest. Dermatol. 67: 561, 1976.Google Scholar
  90. 90.
    Scherer, R. The human peripheral lymphocyte—a model system for studying the combined effect of psoralen plus black light. Klin. Wochenschr. 55: 137–140, 1977.Google Scholar
  91. 91.
    Scherer, R., Kern, B., and Braun-Falco, O. UVA-induced inhibition of proliferation of PHA- stimulated lymphocytes from humans treated with 8-methoxypsoralen. Br. J. Dermatol. 97: 519–527, 1977.Google Scholar
  92. 92.
    Lischka, G., Bohnert, E., Bachtold, G., and Jung, E. G. Effects of 8-methoxypsoralen (8- MOP) and UVA on human lymphocytes. J. Invest. Dermatol. (Abstract) 65 (4): 245, 1977.Google Scholar
  93. 93.
    Edelson, R., Jacobs, D., Brin, M., and Kochevar, L. Lymphocyte sensitivity to 8-methoxypsoralen (8-MOP) and ultraviolet-A (UVA). Clin. Res. 25: 281A, 1977.Google Scholar
  94. 94.
    Horowitz, S., Cripps, D., and Hong, R. Selective T cell killing of human lymphocytes by ultraviolet radiation. Cell. Immunol. 74: 80–86, 1974.Google Scholar
  95. 95.
    Cormane, R. H., Hamerlinck, F., Simon, M., and Siddiqui, A. H. Photoimmunology in psoriasis. J. Invest. Dermatol. (Abstract) 68 (4): 253, 1977.Google Scholar
  96. 96.
    Ortonne, J. P., Claudy, A. L., Alario, A., and Thivolet, J. Decreased circulating E rosette forming cells in psoralen UVA treated patients. Arch. Dermatol. Res. 258: 305–306, 1977.Google Scholar
  97. 97.
    Kraemer, K. H., and Weinstein, G. D. Decreased thymidine incorporation in circulating leukocytes after treatment of psoriasis with psoralen and long-wave ultraviolet light. J. Invest. Dermatol. 69 (2): 211–214, 1977.Google Scholar
  98. 98.
    Clark, D. H. Photosensitization by 8-methoxypsoralen. J. Invest. Dermatol. 37: 171–174, 1961.Google Scholar
  99. 99.
    Griffin, A. C. Methoxsalen in ultraviolet carcinogenesis in the mouse. J. Invest. Dermatol. 32 (Suppl.): 367–372, 1959.Google Scholar
  100. 100.
    O’Neal, M., and Griffin, A. C. The effect of oxypsoralen upon ultraviolet carcinogenecity in albino mice. Cancer Res. 77: 911–916, 1957.Google Scholar
  101. 101.
    Hakim, R. E., Griffin, A. C., and Knox, J. M. Erythema and tumor formation in methoxsalen-treated mice exposed to fluorescent light. Arch. Dermatol. 82: 512–511, 1960.Google Scholar
  102. 102.
    Urbach, F. Modification of ultraviolet carcinogenesis by photoactive agents. J. Invest. Dermatol. 32 (Suppl.): 373–378, 1959.Google Scholar
  103. 103.
    Langner, A., Wolska, H., Jarzabek-Chorzilska, M., and Pawinska, M. Dermal toxicity of 8-methoxypsoralen in hairless mice. J. Invest. Dermatol. 64: 279–280, 1975.Google Scholar
  104. 104.
    Griffin, A. C., Hakim, R. E., and Knox J. The wavelength effect upon erythema and carcinogenic response in psoralentreated mice. J. Invest. Dermatol. 37: 289–295, 1958.Google Scholar
  105. 105.
    MacDonald, E., Griffin, A. C., Hopkins, C., Smith, L., Garrett, H., and Black, G. L. Psoralen prophylaxis against skin cancer: Report of clinical trial. Invest. Dermatol. 41: 213–223, 1963.Google Scholar
  106. 106.
    Cloud, T. M., Hakim, R., and Griffin, A. C. Photosensitization of the eye with methoxsalen. Arch. Ophthalmol. 64: 346–351, 1960.Google Scholar
  107. 107.
    Cloud, T. M., Hakim, R., and Griffin, A. C. Photosensitization of the eye with methoxsalen. II. Chronic effects. Arch. Ophthalmol. 66: 689–694, 1961.Google Scholar
  108. 108.
    Cogan, D. Photosensitization and cataracts. Arch. Ophthalmol. 66: 28–29, 1961.Google Scholar
  109. 109.
    Igali, S., Bridges, B., Ashwood-Smith, M., and Scott, B. Mutagenesis in Escherichia coli. Mutat. Res. 9: 21–30, 1970.Google Scholar
  110. 110.
    Swanbeck, G., and Thyresson, M. Induction of respiration-deficient mutants in yeast by psoralen and light. J. Invest. Dermatol. 63: 242–244, 1974.Google Scholar
  111. 111.
    Carter, D. M., Wolff, K., and Schnedl, W. 8-Methoxypsoralen and UVA promote sisterchromatid exchanges. J. Invest. Dermatol. 67: 548–551, 1976.Google Scholar
  112. 112.
    Wolff-Schreiner, E. C., Carter, M., Schwarzacher, H. G., and Wolff, K. Sister chromatid exchanges in photochemotherapy. J. Invest. Dermatol., 69: 387–391, 1977.Google Scholar
  113. 113.
    Latt, S. A. Sister chromatid exchanges, indices of human chromosome damage and repair: Detection by fluorescence and induction by mitomycin C. Proc. Natl. Acad. Set. USA. 77: 3162–3166, 1974.Google Scholar
  114. 114.
    Wolff, K. Oral methoxsalen photochemotherapy of psoriasis: Results—Follow-up and pathology. In Proceedings of the Second International Symposium on Psoriasis, Stanford University, Stanford, California (E. M. Farber and A. J. Cox, Eds.). Dun-Donnelley, Yorke Medical Books, New York, 1977, pp. 300–309.Google Scholar
  115. 115.
    Wolff, S., Rodin, B., and Cleaver, J. E. Sister chromatid exchanges induced by mutagenic carcinogens in normal and xeroderma pigmentosum cells. Nature 265: 347–349, 1977.Google Scholar
  116. 116.
    Christen, A. G. Ultraviolet radiation and fluorescence in diagnosis, therapy, and research. J. Oral Ther. Pharmacol. 3: 62–79, 1966.Google Scholar
  117. 117.
    Silverstone, L. M. Fissure sealants. Caries Res. 8: 2–26, 1974.Google Scholar
  118. 118.
    Buonocore, M. G. Caries prevention in pits and fissures sealed with an adhesive resin polymerized by ultraviolet light: A two-year study of a single adhesive application. J. Am. Dent. Assoc. 82: 1090–1093, 1971.Google Scholar
  119. 119.
    Payne, T. F. An evaluation of actinic blocking agents for the protection of lip mucosa. J. Am. Dent. Assoc. 92: 409–411, 1976.Google Scholar
  120. 120.
    Wood, R. W. Secret communications concerning light rays. J. Phys. 5e Serie, T. I X, March 1919.Google Scholar
  121. 121.
    Caplan, R. M. Medical uses of the Wood’s lamp. J.A.M.A. 202: 1035–1038, 1967.Google Scholar
  122. 122.
    Gilchrest, B. A., Fitzpatrick, T. B., Anderson, R. R., and Parrish, J. A. Localization of melanin pigmentation in the skin with Wood’s lamp. Br. J. Dermatol. 96: 245–248, 1977.Google Scholar
  123. 123.
    Benedict, H. The fluorescence of teeth as another method of attack on the problem of dental caries. J. Dent. Res. 9: 274, 1929.Google Scholar
  124. 124.
    Hefferren, J., Cooley, R., Hall, J., Olsen, N., and Lyon, H. Use of ultraviolet illumination in oral diagnosis. J. Am. Dent. Assoc. 82: 1353–1360, 1971.Google Scholar

Copyright information

© Plenum Press, New York 1978

Authors and Affiliations

  • John A. Parrish
    • 1
  • R. Rox Anderson
    • 1
  • Frederick Urbach
    • 2
  • Donald Pitts
    • 3
  1. 1.Harvard Medical SchoolUSA
  2. 2.Skin and Cancer HospitalTemple University School of MedicineUSA
  3. 3.College of OptometryUniversity of HoustonUSA

Personalised recommendations